About nautilus biotechnology inc - NAUT
Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal M. Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.
NAUT At a Glance
Nautilus Biotechnology, Inc.
2701 Eastlake Avenue East
Seattle, Washington 98102
| Phone | 1-206-333-2001 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -59,001,000.00 | |
| Sector | Health Technology | Employees | 130 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
NAUT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.571 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.862 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.174 |
NAUT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -453,853.846 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NAUT Liquidity
| Current Ratio | 13.325 |
| Quick Ratio | 13.325 |
| Cash Ratio | 13.004 |
NAUT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -27.198 |
| Return on Equity | -32.267 |
| Return on Total Capital | -31.553 |
| Return on Invested Capital | -28.212 |
NAUT Capital Structure
| Total Debt to Total Equity | 19.124 |
| Total Debt to Total Capital | 16.054 |
| Total Debt to Total Assets | 15.708 |
| Long-Term Debt to Equity | 16.682 |
| Long-Term Debt to Total Capital | 14.004 |